Semax + Selank + DSIP
The trials were run in patients. The buyers are well.
Semax has Russian clinical evidence in stroke and cognitive impairment. Selank has it in generalised anxiety disorder. Both are real. Neither was collected in healthy adults looking for an edge, and that gap is the most important thing about this stack.
Sharp in the morning, calm in the evening, asleep at night.
This is Semax and Selank with DSIP added for the night. The two-compound version is the most common nootropic pairing in peptides, and the halves are chosen to pull in opposite directions on purpose.
Semax is the daytime half. People take it for focus, mental clarity and the ability to keep working when the task is dull, and it is reported to act within about an hour.
Its case is better than most nootropics manage. Semax raises BDNF and NGF. These are growth signals that help brain cells survive and form new connections. That rise has been measured in humans after nasal dosing, not only in rodents.[2] Studies looking across the whole genome show it changing how large sets of genes behave, covering blood vessel tone, inflammation and the brain's ability to rewire.[9] It is registered in Russia for stroke recovery and cognitive deficit, which means a regulator looked at the data and licensed it for those uses.
Selank is the other end. It eases anxiety and mental noise while leaving you clear-headed, which is the specific thing benzodiazepines do not manage. The Russian trial that compared it against one found no sedation.
DSIP is added because poor sleep undoes both. Treating daytime clarity without treating sleep is doing half the job.
Four benefits, and how well each one holds up.
The rows that say human trial were measured in people with a diagnosis. Almost nobody buying this stack has one, and no study has tested any of it in healthy adults.
Three questions, answered before anything else.
What was studied, against what is claimed.
Both Semax and Selank have genuine Russian clinical evidence, and it was collected in populations with something wrong. That is where the money goes in medicine and it is the right place to run a trial. It is also not where the buyers are.
One evidence assessment puts the Semax position bluntly: cognitive enhancement in healthy humans has no published randomised trial and rests on mechanism extrapolation, with confidence rated very low.[2] Another notes that generalising trial effects from stroke patients and anxious patients to healthy high performers is unsupported.[5]
None of that makes the compounds inert. A drug that helps a damaged system does not automatically help an intact one, and it does not automatically fail either. Nobody has run the study.
Selank was tested against a benzodiazepine and held up.
Of everything in this stack, Selank has the best claim to real clinical evidence. Zozulya and colleagues ran a trial in 62 patients with generalised anxiety disorder and neurasthenia, comparing Selank against medazepam, a benzodiazepine.[6]
The reported result was an anxiolytic effect comparable to the benzodiazepine, without the sedation, the cognitive dulling or the dependence.[3] The trial also noted a mild stimulant effect that the comparator did not produce.
A later trial by Medvedev and colleagues ran in 60 patients with phobic anxiety and somatoform disorders. It reported anxiolytic and mild nootropic effects. The benefit persisted about a week after the last dose.[4]
Two things temper that. Both trials are small and neither has been replicated outside Russia. And the numeric effect sizes were not reported in the English-language abstracts, so anyone who does not read Russian cannot see how large the effect actually was.[4] A comparison you cannot quantify is weaker than one you can.
DSIP has no receptor, fifty years on.
DSIP was pulled from the blood of sleeping rabbits in 1977 and named for what it appeared to do. In nearly fifty years since, three things are still missing: the gene that makes it, the protein itself, and any receptor it binds to.
A 2006 review in the Journal of Neurochemistry said so in its title, calling DSIP a still unresolved riddle, and judged the sleep claim extremely poorly documented. Nothing published since has overturned that.
Stranger still, the body's own DSIP runs opposite to the name. When natural levels rise, slow-wave and REM sleep go down rather than up. The Epitalon and DSIP page covers this in full, including what has better evidence for insomnia.
So the stack pairs two compounds with real if narrow clinical evidence with one that has none. Adding DSIP is the step where the evidence base drops sharply.
Registered in Russia, restricted in the United States.
Semax and Selank are both prescription products in Russia, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Neither has FDA approval, and Selank is classified as a Category 2 bulk drug substance, meaning compounding pharmacies cannot use it.[3]
On safety, the Russian trials report both as well tolerated, with no significant sedation, no dependence signal over the study periods and no serious adverse events in the published abstracts.[3] Those study periods ran weeks to months, so long-term human data is limited.[7]
One gap worth naming for anyone on psychiatric medication. Comprehensive interaction studies with SSRIs, SNRIs and MAOIs have not been done.[7] Selank is being taken for anxiety, which is exactly the population most likely to already be on one of those.
No study has given all three compounds together. We searched and found nothing. That is our own search rather than a systematic review, and we will correct this page for anyone who can point us to a trial.
What people ask about this stack
Does Semax improve focus in healthy people?
No published trial has tested that. Semax has Russian clinical evidence in stroke recovery and cognitive impairment, and it is registered there for those uses. One evidence assessment rates cognitive enhancement in healthy humans as having no published randomised trial and resting on mechanism extrapolation, with confidence very low. It might work. Nobody has checked.
How good is the Selank evidence?
The best in this stack. A trial in 62 patients with generalised anxiety disorder compared Selank against medazepam, a benzodiazepine, and reported a comparable anxiolytic effect without sedation, cognitive dulling or dependence. A later trial in 60 patients found the effect persisting about a week after the last dose. Both are small, neither has been replicated outside Russia, and the numeric effect sizes were not published in the English abstracts.
Is DSIP worth adding?
DSIP has the weakest evidence of the three by a wide margin. Fifty years after it was isolated, nobody has identified the gene that makes it, the protein itself or any receptor it binds. A 2006 review called it a still unresolved riddle. The body's own DSIP levels also run opposite to the name, with slow-wave and REM sleep falling when they rise. A premixed Semax and Selank blend costs $32.48 and leaves it out.
Can I take these alongside an antidepressant?
Comprehensive interaction studies with SSRIs, SNRIs and MAOIs have not been done. That gap matters here more than on most pages, because anxiety is the indication Selank is registered for and many people with anxiety are already on one of those medications. This is a conversation for a doctor rather than a forum.
Why is all the research Russian?
Both compounds were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and went through the Russian regulatory system, where they are registered prescription products. The overwhelming majority of published studies are Russian-language, conducted at Russian institutions, and appear on PubMed only as translated abstracts. No Western randomised controlled trials have been completed for either.
Is there a simpler version?
Dropping DSIP leaves Semax and Selank, which are the two compounds with clinical evidence behind them, and a premixed blend of the pair costs $32.48 against $63.99 for all three. Compare against the other stacks.
What this page is built on
The Russian primary literature is largely published in Russian and was not read. Everything below is a secondary account of it, which is part of what this page describes.
- 01Comparison of Semax and Selank. Source for both being developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Semax registration in cerebrovascular and cognitive-deficit contexts, and Selank registration in anxiety.
- 02Evidence ledger grading Semax claims. Cognitive enhancement in healthy humans: no published randomised trial, mechanism extrapolation only, confidence very low. Cognitive outcomes in stroke and ischaemia patients: small Russian trials, not independently replicated, confidence low.
- 03Selank evidence and status review. Source for the Zozulya comparator trial against medazepam, the absence of sedation, the registration in the Russian Federation for generalised anxiety disorder and neurasthenia, FDA Category 2 classification, and the safety reporting in published abstracts.
- 04Medvedev et al., 2014 trial in 60 patients with phobic-anxiety and somatoform disorders, reporting anxiolytic and mild nootropic effects with persistence approximately one week after the last dose. Also the note that numeric effect sizes were not reported in the English-language abstracts.
- 05Head-to-head assessment noting that Russian clinical evidence comes from populations with deficits rather than healthy high performers, and that generalising trial effects to healthy enhancement is unsupported.
- 06Zozulya et al., clinical trial of Selank against medazepam in 62 patients with generalised anxiety disorder and neurasthenia.
- 07Clinical review of Selank noting the absence of comprehensive interaction studies with SSRIs, SNRIs and MAOIs, and that long-term human safety data is limited with most studies running weeks to months.
- 09Comparison noting genome-wide studies showing Semax altering expression of large gene sets involved in vascular tone, inflammation and neuroplasticity, and Selank sharing BDNF-modulating and enkephalin-related effects.
- 08Peptide Decoding vendor pricing data, 16 September 2026. Lowest in-stock single-compound listings: Semax $20.14, Selank $20.14, DSIP $17.00. Premixed Semax and Selank blend from $32.48.